Haem 2 (Myeloid & AML) – Open Studies
s_external_protocol_id Study Details Site Indication Therapeutic Area Sub Therapeutic Area s_recruitment_criteria Sponsor Phase Team Open To Accrual 1 Open to Accrual Date Close to Accrual Date (String) Completely Closed Date (String) Site Initiation Visit Date (String) Inclusion and Exclusion Criteria 2 Notes PI Study Coordinator s_nick s_other_id Inclusion and Exclusion Criteria url Inclusion and Exclusion Criteria Email CTA Site Target Total Recruitment Percentage 13/23 TROG - 12.01 - HPV OROPHARYNX - NC57 A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV OROPHARYNX) PCCTU Head & Neck A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV OROPHARYNX) Trans Tasman Radiation Oncology Group - TROG Phase III PCCTU MoncC No 1/04/2013 13/09/2018 10/05/2013 Danny Rischin Report a correction 40 56 1 15/82 Merck - MK3475-048 - CT755 A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
MK3475-048 PCCTU Head & Neck Cutaneous SCC A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Merck Serono Phase III PCCTU MoncC No 28/05/2015 3/05/2017 7/07/2015 Danny Rischin MK3475-048 Report a correction 8 14 1 16/38 GlaxoSmithKline - 204691 - ICOS - CT824 A Phase I Open Label study of GSK3359609 administered alone and in combination with anticancer agents in subjects with selected advanced solid tumors PCCTU Head & Neck A Phase I Open Label study of GSK3359609 administered alone and in combination with anticancer agents in subjects with selected advanced solid tumors Glaxo Smith Kline - GSK Phase I PCCTU MoncC No 1/07/2016 30/06/2019 30/08/2016 Danny Rischin Report a correction 7 32 1 16/41 Regeneron Pharmaceuticals Inc - R2810-ONC-1540 - Regeneron 2 - CT823 A phase 2 study of REGN2810, a fully human monoclonal antibody to programmed death -1 (PD-1), in patients with advanced cutaneous squamous cell carcinoma
R2810-ONC-1540 PCCTU Head & Neck Cutaneous SCC A phase 2 study of REGN2810, a fully human monoclonal antibody to programmed death -1 (PD-1), in patients with advanced cutaneous squamous cell carcinoma PPD Phase II PCCTU MoncC No 1/07/2016 31/01/2017 12/08/2016 Danny Rischin R2810-ONC-1540 Report a correction 5 58 1 17/09 BMS - CA209-651 - CT867 An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) PCCTU Head & Neck An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Bristol Myers Squibb - BMS Phase III PCCTU MoncC No 1/06/2016 31/03/2016 16/02/2017 Danny Rischin Report a correction 4 10 1 17/13 Merck - MK3475-412 - CT902 A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenanace therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412)
MK3475-412 PCCTU Head & Neck A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenanace therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412) Merck Serono Phase III PCCTU MoncC No 23/06/2017 1/03/2021 21/07/2017 Danny Rischin MK3475-412 Report a correction 6 7 1 17/210 Roche - WO40242 - IMvoke10 - CT972 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti Pd-L1 Antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced Squamous Cell Carcinoma of the head and neck (WO40242) PCCTU Head & Neck A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti Pd-L1 Antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced Squamous Cell Carcinoma of the head and neck (WO40242) Roche Phase III PCCTU MoncC No 27/02/2018 31/05/2021 27/02/2018 Danny Rischin Report a correction 3 1 1 19/127 Loxo Oncology - LOXO-RET-18037 - LIBRETTO-201 - CT1150 LIBRETTO-201
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation
LOXO-RET-18037 PCCTU Head & Neck Thyroid A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation Southern Star Research N/A PCCTU MoncC Yes 1/12/2019 3/02/2020 This study is for any patient with a RET activated cancer who is ineligible for the other available RET targeted trials. It has fixed limits to enrolment per site over specified time periods.
Open for accrual. Ben Solomon LIBRETTO-201 LOXO-RET-18037 Report a correction 5 10 1 19/187 Eli Lilly - J2G-MC-JZJB - LIBRETTO-531 - CT1176 A mulitcentre, randomised, open-label, phase 3 trial comparing LOXO-292 to physicians choice of Cabozantinib or Vandertanib in patients with progressive, advanced, kinase inhibitor naive, RET-mutant medullary thyroid cancer (LIBRETTO-531)
J2G-MC-JZJB PCCTU Head & Neck Thyroid A mulitcentre, randomised, open-label, phase 3 trial comparing LOXO-292 to physicians choice of Cabozantinib or Vandertanib in patients with progressive, advanced, kinase inhibitor naive, RET-mutant medullary thyroid cancer (LIBRETTO-531) Eli Lilly Phase III PCCTU MoncC Yes 1/04/2020 30/04/2020 TK inhibitor. PMCC and COBL open. Alfred also joining.
Worldwide shorage of Vandertanib. Annette Lim J2G-MC-JZJB https://classic.clinicaltrials.gov/ct2/show/NCT04211337?term=NCT04211337&draw=2&rank=1 Click here Report a correction 6 1 1 19/217 Syneos - BGB-3245-AU-001 - MapKure - CT1152 MapKure
A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors
BGB-3245-AU-001 PCCTU Head & Neck Solid Tumour A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors Syneos Phase Ib PCCTU EDD Yes 28/02/2020 16/03/2020 Jayesh Desai EDD PMC MapKure BGB-3245-AU-001 https://classic.clinicaltrials.gov/ct2/show/NCT04249843?term=BGB-3245-AU-001&draw=2&rank=1#eligibility Click here Report a correction 12 12 1 19/233 GSK - 209229 - INDUCE 3 - CT1170 A Randomized, Double-blind, Adaptive, Phase II/III Study of Pembrolizumab with or without GSK3359609 for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma PCCTU Head & Neck Cutaneous SCC A Randomized, Double-blind, Adaptive, Phase II/III Study of Pembrolizumab with or without GSK3359609 for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Glaxo Smith Kline - GSK Phase II/III PCCTU MoncC No 1/12/2019 1/05/2021 3/12/2019 Danny Rischin https://clinicaltrials.gov/ct2/show/NCT04128696?term=NCT04128696&draw=2&rank=1 Click here Report a correction 8 5 1 19/235 Regeneron Pharmaceuticals - R2810-ONC-1901 - CT1180 A phase 2 study of neoadjuvant cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC) PCCTU Head & Neck A phase 2 study of neoadjuvant cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC) ICON Clinical Research Phase II/III PCCTU MoncC No 31/01/2020 1/09/2021 14/04/2020 Danny Rischin Report a correction 5 11 1 19/25 Kura Oncology - KO-TIP-007 - CT1111 The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN) PCCTU Head & Neck The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN) PRA International N/A PCCTU MoncC No 12/08/2019 11/05/2022 26/07/2019 Danny Rischin Report a correction 3 0 1 19/68 Regeneron Pharmaceuticals Inc - R3767-ONC-1613 - CT1116 A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies PCCTU Head & Neck A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies ICON Clinical Research Phase I PCCTU MoncC No 10/10/2019 22/03/2022 30/10/2019 Danny Rischin Report a correction 8 4 1 19/87 Regeneron Pharmaceuticals - R2810-ONC-1788 - cPOST - CT1126 cPOST
A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.
R2810-ONC-1788 PCCTU Adjuvant Head & Neck Cutaneous SCC A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. ICON Clinical Research Phase III PCCTU MoncC Yes 1/08/2019 3/09/2019 Anti-PD-1 monoclonal antibody.
Amendment underway to broaden the inclusion criteria.
Recruitment slow. Danny Rischin cPOST R2810-ONC-1788 https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=R2810-ONC-1788&draw=2&rank=1#eligibility Click here Report a correction 20 20 1 19/87 Regeneron Pharmaceuticals - R2810-ONC-1788 - cPOST - CT1126 cPOST
A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.
R2810-ONC-1788 PCCTU Neo-adjuvant Head & Neck Cutaneous SCC A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. ICON Clinical Research Phase III PCCTU MoncC Yes 1/08/2019 3/09/2019 Anti-PD-1 monoclonal antibody.
Amendment underway to broaden the inclusion criteria.
Recruitment slow. Danny Rischin cPOST R2810-ONC-1788 https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=R2810-ONC-1788&draw=2&rank=1#eligibility Click here Report a correction 20 20 1 20/01 Decibel Therapeutics - DB-020-002 - CT1183 Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Doses of DB-020 in Patients Receiving Cisplatin PCCTU Head & Neck Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Doses of DB-020 in Patients Receiving Cisplatin Syneos Phase I PCCTU MoncC No 15/12/2019 24/11/2022 3/02/2020 Danny Rischin Report a correction 4 7 1 20/044 - IMPARP-HRD - VC007 IMPARP-HRD
An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects
20/044, VC007 PCCTU Head & Neck Solid Tumour An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects Peter MacCallum Cancer Centre Phase II PCCTU EDD Yes 20/01/2022 20/01/2022 Stephen Luen EDD PMC IMPARP-HRD 20/044, VC007 https://clinicaltrials.gov/ct2/show/NCT04985721?term=NCT04985721&draw=2&rank=1 Click here Report a correction 10 16 1 20/044 - IMPARP-HRD - VC007 IMPARP-HRD
An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects
20/044, VC007 Western Health Head & Neck Solid Tumour An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects Peter MacCallum Cancer Centre Phase II Yes 29/05/2023 29/05/2023 Keri-Lee Geneser IMPARP-HRD 20/044, VC007 https://clinicaltrials.gov/ct2/show/NCT04985721?term=NCT04985721&draw=2&rank=1 Click here Report a correction 15 1 1 20/152 GSK - 209227 - INDUCE-4 - CT1255 A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma PCCTU Head & Neck Cutaneous SCC A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Glaxo Smith Kline - GSK Phase II/III PCCTU MoncC No 31/07/2020 1/05/2021 10/09/2020 Annette Lim https://clinicaltrials.gov/ct2/show/NCT04428333?term=NCT04428333&draw=2&rank=1 Click here Report a correction 5 6 1 20/214 AstraZeneca - D7310C00001 - Interlink-1 - CT1284 A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor PCCTU Head & Neck A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor AstraZeneca Phase III PCCTU MoncC No 18/09/2020 1/08/2022 27/10/2021 Danny Rischin PCCTU MoncC Team Report a correction 10 11 1 20/236 Debiopharm - 1143-SCCHN-301 - CT1298 A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX). PCCTU Head & Neck A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX). Syneos Phase III PCCTU MoncC No 15/11/2020 25/02/2022 23/11/2020 Annette Lim Report a correction 5 0 1 2014.009 Exelixis - XL184-401 - CT720 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients. PCCTU Head & Neck A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients. PPD Phase III PCCTU MoncC No 1/04/2015 28/02/2018 1/05/2015 Jeanne Tie Report a correction 1 4 1 21/125 - NORTH - CP-MGA271-06 - CT1350 A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination with Retifanlimab or Tebotelimab in the First-Line Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Barwon Head & Neck A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination with Retifanlimab or Tebotelimab in the First-Line Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Novotech Phase II Medical Oncology No 8/11/2021 7/07/2022 28/10/2021 Madhu Singh Report a correction 2 0 1 21/166 - AstraZeneca - D6900C00001 - B7H4 - Astra Solid - CT1427 (EDD - Primary) A Phase I/IIa Multi-center, Open-label, Modular Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 as Monotherapy and in Combination with Anticancer Agents, in Participants with Advanced or Metastatic Solid Malignancies
D6900C00001 PCCTU Head & Neck Solid Tumour A Phase I/IIa Multi-center, Open-label, Modular Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 as Monotherapy and in Combination with Anticancer Agents, in Participants with Advanced or Metastatic Solid Malignancies AstraZeneca Phase I/IIa PCCTU EDD Yes 23/11/2021 15/11/2021 Linda Mileshkin EDD PMC D6900C00001 https://classic.clinicaltrials.gov/ct2/show/NCT05123482?term=D6900C00001&draw=2&rank=1#eligibility Click here Report a correction 10 12 1 21/168 ALX Oncology - AT148003 - ASPEN-03 - CT1423 A Phase 2 Study of ALX148 in combination with Pembrolizumab in Patients with Advanced head and neck Squamous Cell Carcinoma (Aspen-03)AT148003 PCCTU 1st Line Head & Neck Cutaneous SCC A Phase 2 Study of ALX148 in combination with Pembrolizumab in Patients with Advanced head and neck Squamous Cell Carcinoma (Aspen-03) IQVIA Phase II PCCTU MoncC Yes 19/10/2021 26/10/2021 accruing well Danny Rischin AT148003 https://classic.clinicaltrials.gov/ct2/show/NCT04675294?term=AT148003&draw=2&rank=1#eligibility Click here Report a correction 5 3 1 21/172 ALX Oncology - AT148004 - ASPEN-04 - CT1424 A Phase 2 Study of ALX148 in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma
AT148004 PCCTU 1st Line Head & Neck Cutaneous SCC A Phase 2 Study of ALX148 in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma IQVIA Phase II PCCTU MoncC Yes 19/10/2021 26/10/2021 accruing well Annette Lim AT148004 https://classic.clinicaltrials.gov/ct2/show/NCT04675333?term=AT148004&draw=2&rank=1#eligibility Click here Report a correction 5 11 1 21/46 Erasca - ERAS-601-01 - FLAGSHP-1 - CT1358 (Monc B - Secondary) FLAGSHP-1
An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS601 SHP2 Inhibitor as a Monotherapy and in Combination with Other Anti-Cancer
Therapies in Patients with Advanced or Metastatic Solid Tumors (FLAGSHP-1)
ERAS-601-01 PCCTU Head & Neck Solid Tumour An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS601 SHP2 Inhibitor as a Monotherapy and in Combination with Other Anti-Cancer
Therapies in Patients with Advanced or Metastatic Solid Tumors (FLAGSHP-1) IQVIA Phase Ib PCCTU MoncB Yes 28/06/2021 15/07/2021 Danny Rischin FLAGSHP-1 ERAS-601-01 https://classic.clinicaltrials.gov/ct2/show/NCT04670679?term=ERAS-601-01&draw=2&rank=1 Click here Report a correction 8 1 1 21/46 Erasca - ERAS-601-01 - FLAGSHP-1 - CT1358 (Monc C - Primary) FLAGSHP-1
An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS601 SHP2 Inhibitor as a Monotherapy and in Combination with Other Anti-Cancer
Therapies in Patients with Advanced or Metastatic Solid Tumors (FLAGSHP-1)
ERAS-601-01 PCCTU Head & Neck Solid Tumour An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS601 SHP2 Inhibitor as a Monotherapy and in Combination with Other Anti-Cancer
Therapies in Patients with Advanced or Metastatic Solid Tumors (FLAGSHP-1) IQVIA Phase Ib PCCTU MoncC Yes 28/06/2021 15/07/2021 Danny Rischin FLAGSHP-1 ERAS-601-01 https://classic.clinicaltrials.gov/ct2/show/NCT04670679?term=ERAS-601-01&draw=2&rank=1 Click here Report a correction 8 1 1 22/128 - Axelia Oncology Pty Ltd. - AXA-042-FIH-01 - CT1478 A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with checkpoint inhibitors in subjects with advanced solid tumors.AXA-042-FIH-01 PCCTU Head & Neck Solid Tumour A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with checkpoint inhibitors in subjects with advanced solid tumors. Axelia Oncology Pty Ltd Phase I PCCTU EDD Yes 10/02/2023 6/09/2022 Ben Tran AXA-042-FIH-01 Report a correction 15 2 1 22/205 - AstraZeneca - D9350C00001 - AZD9592 - EGRET - CT1560 AZD9592 EGRET
A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors
D9350C00001 PCCTU Head & Neck Solid Tumour A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors AstraZeneca Phase I PCCTU EDD Yes 19/01/2023 12/01/2023 Ben Solomon AZD9592 EGRET D9350C00001 https://classic.clinicaltrials.gov/ct2/show/NCT05647122?term=D9350C00001&draw=2&rank=1#eligibility Click here Report a correction 8 3 1 22/216 - SpringWorks Therapeutics, Inc - MEKRAF-AST-101 - CT1569 A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients with Advanced Solid Tumors
MEKRAF-AST-101 PCCTU Head & Neck Solid Tumour A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients with Advanced Solid Tumors ADVANCED CLINICAL PTY LTD Phase I/IIa PCCTU EDD Yes 6/04/2023 4/04/2023 Jayesh Desai MEKRAF-AST-101 https://classic.clinicaltrials.gov/ct2/show/NCT05580770?term=MEKRAF-AST-101&draw=2&rank=1#eligibility Click here Report a correction 8 2 1 22/30 - ONJ2021-006 I-FIRST NC292 A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients with RAIR Thyroid Cancer (I-FIRST study) PCCTU Head & Neck Thyroid A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients with RAIR Thyroid Cancer (I-FIRST study) ONJ Cancer Research Institute Phase II PCCTU MoncC Yes 1/03/2022 1/03/2022 Annette Lim Report a correction 2 2 1 22/34 Antengene - ATG-101-001 (PROBE) - CT1471 PROBE
A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
ATG-101-001 PCCTU Head & Neck Solid Tumour A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas Phase I PCCTU EDD Yes 3/03/2022 30/03/2022 Annette Lim PROBE ATG-101-001 https://clinicaltrials.gov/ct2/show/NCT04986865?term=NCT04986865&draw=2&rank=1 Click here Report a correction 10 1 1 23/123 - IO Biotech - IO102-IO 103-032 - IOB?032/PN?E40 - CT IOB?032/PN?E40
Phase II, multi?cohort trial of neoadjuvant and post?surgery IO102?IO103 and pembrolizumab in patients with selected resectable tumors
IO102-IO 103-032 PCCTU Head & Neck Cutaneous SCC Phase II, multi?cohort trial of neoadjuvant and post?surgery IO102?IO103 and pembrolizumab in patients with selected resectable tumors Accelagen Phase II PCCTU MoncC Yes 12/10/2023 Annette Lim PCCTU MoncC Team IOB?032/PN?E40 IO102-IO 103-032 https://classic.clinicaltrials.gov/ct2/show/NCT05280314?term=IO102-IO+103-032&draw=2&rank=1 Click here Report a correction 2 0 1 23/130 - Genentech - GO44431 - CT1666 GO44431
A phase I, open label, multicenter, dose escalation study evaluating the safety, pharmacokinetics, and activity of RO7566802 as a single agent and in combination with Atezolizumab in patients with locally advanced or metastatic solid tumors
GO44431 PCCTU Head & Neck Solid Tumour A phase I, open label, multicenter, dose escalation study evaluating the safety, pharmacokinetics, and activity of RO7566802 as a single agent and in combination with Atezolizumab in patients with locally advanced or metastatic solid tumors PPD Australia Pty Ltd Phase I PCCTU EDD Yes 26/09/2023 Ben Tran GO44431 GO44431 https://classic.clinicaltrials.gov/ct2/show/NCT06031441?term=GO44431&draw=2&rank=1#eligibility Click here Report a correction 12 0 1 23/171 - Gilead - GS-US-521-6317 - CT1689 A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti�PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
GS-US-521-6317 PCCTU Head & Neck Solid Tumour A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti�PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors Gilead Sciences Pty Ltd Phase I PCCTU EDD Yes 31/10/2023 Jayesh Desai PCCTU EDD Team GS-US-521-6317 https://classic.clinicaltrials.gov/ct2/show/NCT06082960?term=GS-US-521-6317&draw=2&rank=1#eligibility Click here Report a correction 10 0 1 23/49 - Regeneron Pharmaceuticals, Inc - CMP-001-009 - CT1614 CMP-001-009
A multicenter, open-label, phase 2 study of intratumoral Vidutolimod (CMP-001) in combination with intravenous Cemiplimab in subjects with selected types of advanced or metastatic cancer.
CMP-001-009 PCCTU Head & Neck Solid Tumour A multicenter, open-label, phase 2 study of intratumoral Vidutolimod (CMP-001) in combination with intravenous Cemiplimab in subjects with selected types of advanced or metastatic cancer. IQVIA Phase II Yes 4/10/2023 24/10/2023 Annette Lim PCCTU MoncC Team CMP-001-009 CMP-001-009 https://classic.clinicaltrials.gov/ct2/show/NCT04916002?term=CMP-001-009&draw=2&rank=1 Click here Report a correction 8 0 1 Allucent - RMC-6291-001 - CT1678 Allucent
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors
RMC-6291-001 SWH Head & Neck Solid Tumour Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors Pharm-Olam International Pty Ltd Phase Ib/II Yes 26/10/2023 Theresa Hayes Allucent RMC-6291-001 https://clinicaltrials.gov/ct2/show/NCT05462717?term=RMC-6291-001&draw=2&rank=1 Click here Report a correction 5 0 1 Antido Therapeutics - AT-0174-001 - CT1692 Antido
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid MalignanciesAT-0174-001 Grampians Health Head & Neck Solid Tumour A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies Antido Therapeutics (Australia) Pty Ltd Phase I Yes 19/10/2023 Lizzie Lim Antido AT-0174-001 Report a correction 3 0 1 Aulos Bioscience, Inc - CP-AU-007-01 - CT1542 CT1542
A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer
CP-AU-007-01 Western Health Head & Neck Solid Tumour A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer PPD Phase I/II Yes 26/10/2023 PHASE 1 TRIALMETASTATIC/Advanced patients Catherine Oakman CT1542 CP-AU-007-01 https://clinicaltrials.gov/ct2/show/NCT05267626?term=NCT05267626&draw=2&rank=1 Click here Report a correction 1 0 1 Aulos Bioscience, Inc - CP-AU-007-01 CT1542 CT1542
A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer
CP-AU-007-01 Alfred - Medical Oncology Head & Neck Solid Tumour A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer PPD Phase I/II ACT 1 Yes 5/11/2022 27/10/2022 PHASE 1 TRIALMETASTATIC/Advanced patients Andrew Haydon CT1542 CP-AU-007-01 https://clinicaltrials.gov/ct2/show/NCT05267626?term=NCT05267626&draw=2&rank=1 Click here Report a correction 5 7 1 Beigene - BGB-900-105 (AdvanTIG-105) - CT1468 Phase 1/1b Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors
BGB-900-105 Bendigo Head & Neck Solid Tumour Phase 1/1b Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Phase Ib Yes 7/03/2022 28/02/2022 Sam Harris BGB-900-105 https://classic.clinicaltrials.gov/ct2/show/NCT04047862?term=NCT04047862&draw=2&rank=1 Click here Report a correction 2 2 1 Celgene BMS - IM043004 - CT1639 IM043004
A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors
IM043004 Peninsula Health Head & Neck Solid Tumour A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors Celgene Pty Limited, a Bristol Myers Squibb company Phase I Yes 13/10/2023 Jacquelyn Thomson IM043004 IM043004 https://classic.clinicaltrials.gov/ct2/show/NCT05625412?term=BMS-986360%2FCC-90001&draw=2&rank=1#eligibility Click here Report a correction 3 0 1 Covance - ATG-101-001 - PROBE - CT1471 PROBE
A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
ATG-101-001 Alfred - Medical Oncology Head & Neck Solid Tumour A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas Antengene (AUS) PTY. LTD Phase I ACT 1 Yes 30/03/2022 23/03/2022 Mark Voskoboynik PROBE ATG-101-001 https://clinicaltrials.gov/ct2/show/NCT04986865?term=NCT04986865&draw=2&rank=1 Click here Report a correction 8 4 1 DynamiCure Biotechnology - DCSZ11-101 - CT1636 A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy in Patients with Advanced or Metastatic Solid Tumors
DCSZ11-101 Cabrini Head & Neck Solid Tumour A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy in Patients with Advanced or Metastatic Solid Tumors Novotech Phase I Yes 2/11/2023 Gary Richardson DCSZ11-101 https://classic.clinicaltrials.gov/ct2/show/NCT05785754?term=DCSZ11-101&draw=2&rank=1 Click here Report a correction 6 0 1 George Clinical - CIBI334A101 - INNOVENT - CT1644 INNOVENT
A Phase 1 Study of IBI334 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors
CIBI334A101 Grampians Health Head & Neck Solid Tumour A Phase 1 Study of IBI334 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors The George Institute Phase I Yes 17/07/2023 5/07/2023 Lizzie Lim INNOVENT CIBI334A101 https://classic.clinicaltrials.gov/ct2/show/NCT05774873?term=CIBI334A101&draw=2&rank=1 Click here Report a correction 12 0 1 Gilead - GS-US-548-5916 - ELEVATE HNSCC - CT1537 ELEVATE HNSCC
A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma
GS-US-548-5916 Alfred - Medical Oncology 1st Line Head & Neck Cutaneous SCC A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma Gilead Phase II ACT 3 Yes 21/09/2022 13/10/2022 Miles Andrews ELEVATE HNSCC GS-US-548-5916 https://classic.clinicaltrials.gov/ct2/show/NCT04854499?term=GS-US-548-5916&draw=2&rank=1#eligibility Click here Report a correction 3 1 1 Gilead - GS-US-548-5916 - ELEVATE HNSCC - CT1537 ELEVATE HNSCC
A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma
GS-US-548-5916 Alfred - Medical Oncology Adjuvant Head & Neck Cutaneous SCC A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma Gilead Phase II ACT 3 Yes 21/09/2022 13/10/2022 Miles Andrews ELEVATE HNSCC GS-US-548-5916 https://classic.clinicaltrials.gov/ct2/show/NCT04854499?term=GS-US-548-5916&draw=2&rank=1#eligibility Click here Report a correction 3 1 1 Gilead - GS-US-548-5916 - ELEVATE HNSCC - CT1537 ELEVATE HNSCC
A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma
GS-US-548-5916 Alfred - Medical Oncology Neo-adjuvant Head & Neck Cutaneous SCC A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma Gilead Phase II ACT 3 Yes 21/09/2022 13/10/2022 Miles Andrews ELEVATE HNSCC GS-US-548-5916 https://classic.clinicaltrials.gov/ct2/show/NCT04854499?term=GS-US-548-5916&draw=2&rank=1#eligibility Click here Report a correction 3 1 1 IQVIA - LM302-01-201 - LANOVA - CT1476 LANOVA
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-302 in Combination with Toripalimab in Patients with Advanced Solid Tumors
LM302-01-201 Alfred - Medical Oncology Head & Neck Solid Tumour A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-302 in Combination with Toripalimab in Patients with Advanced Solid Tumors IQVIA Phase I/II ACT 1 Yes 22/04/2022 21/04/2022 Ben Markman LANOVA LM302-01-201 https://classic.clinicaltrials.gov/ct2/show/NCT05188664?term=NCT05188664&draw=2&rank=1 Click here Report a correction 3 7 1 MSD - MK-3475-630 - KEYNOTE-630 - CT1137 KEYNOTE-630
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC)
MK-3475-630 Alfred - Medical Oncology Adjuvant Head & Neck Cutaneous SCC A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) Merck Serono Phase III ACT 2 Yes 23/08/2019 7/08/2019 Anti-PD-1 immunotherapy
Adjuvant therapy for locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy Mitchell Chipman Jane Berry KEYNOTE-630 MK-3475-630 https://classic.clinicaltrials.gov/ct2/show/NCT03833167?term=MK-3475-630&draw=2&rank=1#eligibility Click here Report a correction 5 10 1 Maverick Therapeutics - CP-MVC-101-01 - CT1632 COBRA
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 Conditional Bispecific Redirected Activation Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer
CP-MVC-101-01 Alfred - Medical Oncology Head & Neck Solid Tumour A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 Conditional Bispecific Redirected Activation Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer PPD Phase I/II Yes 15/06/2023 25/05/2023 Andrew Haydon COBRA CP-MVC-101-01 https://clinicaltrials.gov/ct2/show/NCT04844073?term=NCT04844073&draw=2&rank=1 Click here Report a correction 5 1 1 Multitude Therapeutics - AMT11601 - CT1634 AMT-116-01
First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
AMT11601 Cabrini Head & Neck Solid Tumour First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors Multitude Therapeutics Phase I Yes 22/09/2023 20/09/2023 Gary Richardson AMT-116-01 AMT11601 https://classic.clinicaltrials.gov/ct2/show/NCT05725291?term=AMT116-01&draw=2&rank=1 Click here Report a correction 6 0 1 No CTA Finance - PMCC sponsored - DISCERN - NC Comprehensive and deep profiling in cutaneous squamous cell carcinomas to unravel treatment efficacy in immunotherapy treated patients PCCTU Head & Neck Cutaneous SCC Comprehensive and deep profiling in cutaneous squamous cell carcinomas to unravel treatment efficacy in immunotherapy treated patients PMCC Sponsored N/A Yes 23/05/2023 23/05/2023 Annette Lim https://clinicaltrials.gov/ct2/show/NCT05878288?term=DISCERN&draw=2&rank=3 Click here Report a correction 10 4 1 Novotech - MHB036C-CP001EN - CT1561 MHB036C
Phase 1/2, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants with Advanced or Metastatic Solid Tumors
MHB036C-CP001EN Cabrini Head & Neck Solid Tumour Phase 1/2, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants with Advanced or Metastatic Solid Tumors Novotech Phase I/II Yes 9/03/2023 Gary Richardson MHB036C MHB036C-CP001EN https://classic.clinicaltrials.gov/ct2/show/NCT05642949?term=MHB036C-CP001EN&draw=2&rank=1#eligibility Click here Report a correction 5 0 1 Novotech - MHB088C-CP001EN - CT1570 MHB088C
Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants with Advanced or Metastatic Solid Tumors
MHB088C-CP001EN Cabrini Head & Neck Solid Tumour Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants with Advanced or Metastatic Solid Tumors Novotech Phase I/II Yes 9/03/2023 Gary Richardson MHB088C MHB088C-CP001EN https://classic.clinicaltrials.gov/ct2/show/NCT05652855?term=MHB088C-CP001EN&draw=2&rank=1#eligibility Click here Report a correction 5 0 1 Nuvation Bio - NUV-868-01 - CT1586 Phase 1/2 Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NUV-868-01 Cabrini Head & Neck Solid Tumour Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Novotech Phase I/II Yes 21/08/2023 8/08/2023 Shehara Mendis Phase 1/2 Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868-01 https://classic.clinicaltrials.gov/ct2/show/NCT05252390?term=NUV-868-01&draw=2&rank=1 Click here Report a correction 6 1 1 Nuvation Bio - NUV-868-01 - CT1586 Phase 1/2 Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NUV-868-01 PCCTU Head & Neck Solid Tumour Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Novotech Phase I/II PCCTU MoncA Yes 15/08/2023 15/08/2023 Arun Azad PCCTU MoncA Team Phase 1/2 Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868-01 https://classic.clinicaltrials.gov/ct2/show/NCT05252390?term=NUV-868-01&draw=2&rank=1 Click here Report a correction 8 1 1 PMCC Sponsored - Cancer Statewide_26072023 - NC Cancer Statewide
A hybrid type III effectiveness and implementation trial of complex genomic profiling in patients with advanced cancer using three models of care in metropolitan and regional oncology centres in Victoria, Australia
Cancer Statewide_26072023 GVH Head & Neck Other A hybrid type III effectiveness and implementation trial of complex genomic profiling in patients with advanced cancer using three models of care in metropolitan and regional oncology centres in Victoria, Australia PMCC Sponsored Phase III Yes 14/09/2023 Arvind Sahu Cancer Statewide Cancer Statewide_26072023 Report a correction 35 0 1 PMCC sponsored - 20/044 - IMPARP-HRD - VC007 IMPARP-HRD
An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects
20/044, VC007 St Vincent's Hospital - Medical Oncology Head & Neck Solid Tumour An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects PMCC Sponsored Phase II Yes 5/07/2022 5/07/2022 Genni Newnham IMPARP-HRD 20/044, VC007 https://clinicaltrials.gov/ct2/show/NCT04985721?term=NCT04985721&draw=2&rank=1 Click here Report a correction 0 1 PharmaSols - MT-5111_001 - CT1464 5111_001
A Phase 1b open-label, multicenter dose escalation and expansion study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors
MT - 5111_001 GVH Head & Neck Solid Tumour A Phase 1b open-label, multicenter dose escalation and expansion study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors Molecular Templates Inc Phase I Yes 11/02/2022 11/02/2022 Stage: Metastatic Breast Cancer
Tumour agnostic, HER2 altered Breast cancer expansion arm Must have HER2 expression on latest biopsy of a metastatic deposit Can be HER2 IHC2+ and non ISH-amplified Breast cancer cohort now in expansion Maximum tolerated dose reached in non-breast cohort Arvind Sahu 5111_001 MT - 5111_001 https://classic.clinicaltrials.gov/ct2/show/NCT04029922?term=NCT04029922&draw=2&rank=1#eligibility Click here Report a correction 4 0 1 PharmaSols - MT-5111_001 - CT1464 5111_001
A Phase 1b open-label, multicenter dose escalation and expansion study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors
MT-5111_001 Western Health Head & Neck Solid Tumour A Phase 1b open-label, multicenter dose escalation and expansion study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors Phase Ib Team A No 11/03/2022 31/03/2023 7/03/2022 Stage: Metastatic Breast Cancer
Tumour agnostic, HER2 altered Breast cancer expansion arm Must have HER2 expression on latest biopsy of a metastatic deposit Can be HER2 IHC2+ and non ISH-amplified Breast cancer cohort now in expansion Maximum tolerated dose reached in non-breast cohort Catherine Oakman Lisa Magee 5111_001 MT-5111_001 https://classic.clinicaltrials.gov/ct2/show/NCT04029922?term=NCT04029922&draw=2&rank=1#eligibility Click here Report a correction 5 0 1 R2810-ONC-1788 CT1126 cPOST
A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.
R2810-ONC-1788 Bendigo Adjuvant Head & Neck Cutaneous SCC A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. Regeneron Pharmaceuticals Phase III Yes 3/09/2020 24/06/2020 Anti-PD-1 monoclonal antibody.
Amendment underway to broaden the inclusion criteria.
Recruitment slow. Sam Harris cPOST R2810-ONC-1788 https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=NCT03969004&draw=2&rank=1#eligibility Click here Report a correction 4 4 1 R2810-ONC-1788 CT1126 cPOST
A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.
R2810-ONC-1788 Bendigo Neo-adjuvant Head & Neck Cutaneous SCC A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. Regeneron Pharmaceuticals Phase III Yes 3/09/2020 24/06/2020 Anti-PD-1 monoclonal antibody.
Amendment underway to broaden the inclusion criteria.
Recruitment slow. Sam Harris cPOST R2810-ONC-1788 https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=NCT03969004&draw=2&rank=1#eligibility Click here Report a correction 4 4 1 Regeneron Pharmaceuticals - R2810-ONC-1788 - cPOST - CT1126 cPOST
A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.
R2810-ONC-1788 St Vincent's Hospital - Medical Oncology Head & Neck Cutaneous SCC A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. ICON Clinical Research Phase III Yes 31/10/2019 31/10/2019 Christopher Hart cPOST R2810-ONC-1788 https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=NCT03969004&draw=2&rank=1#eligibility Click here Report a correction 0 1 RemeGen Co. - RC198-G001 - CT1604 CT1604
A Phase 1, First-in-Human, Multicenter, Open-Label Study in Subjects with Locally Advanced Unresectable or Metastatic Solid TumorsRC198-G001 Cabrini Head & Neck Solid Tumour A Phase 1, First-in-Human, Multicenter, Open-Label Study in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors Novotech Phase I Yes 9/08/2023 26/07/2023 Gary Richardson CT1604 RC198-G001 https://classic.clinicaltrials.gov/ct2/show/NCT05867303?term=RC198-G001&draw=2&rank=1 Click here Report a correction 5 1 1 Servier - CL1-95012-001 - CT1463 CT1463
A FIRST IN HUMAN PHASE 1/2 OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF PRS-344/S095012 IN PATIENTS WITH SOLID TUMORS
CL1-95012-001 Cabrini Head & Neck Solid Tumour A FIRST IN HUMAN PHASE 1/2 OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF PRS-344/S095012 IN PATIENTS WITH SOLID TUMORS Servier laboratories (AUST.) Phase I/II Yes 3/06/2022 26/05/2022 Gary Richardson CT1463 CL1-95012-001 https://classic.clinicaltrials.gov/ct2/show/NCT05159388?term=CL1-95012-001&draw=2&rank=1 Click here Report a correction 5 1 1 Surface Oncology - SRF617-101 - CT1466 A Phase I Study of SRF617 in Patients with Advanced Solid Tumours Cabrini Head & Neck Solid Tumour A Phase I Study of SRF617 in Patients with Advanced Solid Tumours Clinipace Phase I Yes 22/06/2022 22/06/2022 PHASE 1 Study Gary Richardson Report a correction 5 1 1 Tigermed - AMT-253-01 - AMT253-01 - CT1679 AMT253-01
First-in-Human, Phase 1 Study of AMT-253, an Anti MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
AMT-253-01 Cabrini Head & Neck Solid Tumour First-in-Human, Phase 1 Study of AMT-253, an Anti MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors Multitude Therapeutics Phase I Yes 3/11/2023 2/11/2023 Gary Richardson AMT253-01 AMT-253-01 https://classic.clinicaltrials.gov/ct2/show/NCT05906862?term=AMT-253-01&draw=2&rank=1 Click here Report a correction 5 0 1 UPCOMING - BMS - CA052002 - CT1620 A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors
CA052002 Cabrini Head & Neck Solid Tumour A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors Bristol Myers Squibb Phase I/II Yes 14/08/2023 14/08/2023 Anis Hamid CA052002 https://clinicaltrials.gov/ct2/show/NCT04895709?term=CA052-002&draw=2&rank=1 Click here Report a correction 12 1 1 UPCOMING - PharmAbcine - MArkV-01 - KEYNOTE-E80 - CT KEYNOTE-E80
A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors
MarkV-01 Grampians Health Head & Neck Solid Tumour A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors Novotech Phase Ib Yes 6/11/2023 Lizzie Lim KEYNOTE-E80 MarkV-01 https://classic.clinicaltrials.gov/ct2/show/NCT05957081?term=MarkV-01&recrs=ab&draw=2&rank=1 Click here Report a correction 3 0 1 Study Details Site Indication Sub Therapeutic Area Phase PI
Haem 2 (Myeloid & AML) – Upcoming Studies
| s_external_protocol_id | Study Details | Site | Indication | Therapeutic Area | Sub Therapeutic Area | s_recruitment_criteria | Sponsor | Phase | Team | Open To Accrual | Open to Accrual Date (String) | Close to Accrual Date (String) | Completely Closed Date (String) | Site Initiation Visit Date (String) | Inclusion and Exclusion Criteria 2 | Notes | PI | Study Coordinator | s_nick | s_other_id | Inclusion and Exclusion Criteria url | Inclusion and Exclusion Criteria | Email CTA | Site Target | Total Recruitment | Percentage |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGEN - 20180144 - AMG144 | AMG144 A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors 20180144 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors | Amgen | Phase I | Yes | AMG144 | 20180144 | https://classic.clinicaltrials.gov/ct2/show/NCT04362748?term=NCT04362748&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||
| Adlai Nortye Biopharma - AN2025H0301 - BURAN | The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Border Medical Oncology | Head & Neck | Cutaneous SCC | The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Adlai Nortye Biopharma Co. | Phase III | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04338399?term=NCT04338399&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Akesobio - AK105-101 | A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid TumorsAK105-101 | Border Medical Oncology | Head & Neck | Solid Tumour | A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors | Akesobio Australia Pty Ltd | Phase I | Yes | AK105-101 | https://classic.clinicaltrials.gov/ct2/show/NCT03352531?term=NCT03352531&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | ||||||||||||
| Akesobio - AK112-01 | AK112-01 A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects with Advanced Solid TumorsAK112-01 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects with Advanced Solid Tumors | Akesobio | Phase I | Yes | AK112-01 | AK112-01 | https://classic.clinicaltrials.gov/ct2/show/NCT04047290?term=NCT04047290&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||
| Arcus Biosciences - AB154CSP0001 | A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | Border Medical Oncology | Head & Neck | Solid Tumour | A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | Arcus Biosciences Australia Pty Ltd. | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT03628677?term=NCT03628677&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Ascendis Pharma Oncology Division - TCTLR-101 | Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | Ascendis Pharma Oncology Division A/S | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04799054?term=NCT04799054&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Aulos Bioscience, Inc - CP-AU-007-01 - CT1542 | CT1542 A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer CP-AU-007-01 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer | Aulos Bioscience, Inc | Phase I/II | Yes | Binds IL-2. | Sophia Frentzas | A M | CT1542 | CP-AU-007-01 | https://clinicaltrials.gov/ct2/show/NCT05267626?term=NCT05267626&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | ||||||||
| BMS - CA209-651 - CheckMate 651 | An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Monash Health - Oncology Department | Head & Neck | Cutaneous SCC | An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Bristol-Myers Squibb (BMS) | Phase III | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02741570?term=NCT02741570&draw=1&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| BeiGene - BGB-900-105 - TIGIT | TIGIT Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid TumorsBGB-900-105 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | Beigene | Phase Ib | Yes | TIGIT | BGB-900-105 | https://classic.clinicaltrials.gov/ct2/show/NCT04047862?term=NCT04047862&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||
| BeiGene - BGB-900-105 - TIGIT | TIGIT Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid TumorsBGB-900-105 | St Vincent's Hospital - Medical Oncology | Head & Neck | Solid Tumour | Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | Beigene | Phase Ib | Yes | TIGIT | BGB-900-105 | https://classic.clinicaltrials.gov/ct2/show/NCT04047862?term=NCT04047862&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||
| BeiGene - BGB-A317-3111 | A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors | Monash Health - Haematology Department | Head & Neck | Solid Tumour | A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors | Beigene | Phase I/II | Yes | https://clinicaltrials.gov/ct2/show/NCT04282018?term=NCT04282018&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| BeiGene - BGB-A317-3111-10188-101 | A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors | Monash Health - Oncology Department | Head & Neck | Solid Tumour | A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors | Beigene | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04282018?term=NCT04282018&draw=1&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| BeiGene - BGB-A317-A445-101 - OX40 | Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | Beigene | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04215978?term=NCT04215978&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| BeiGene - ICP-CL-00303 | A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations | Monash Health - Oncology Department | Head & Neck | Solid Tumour | A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations | Beigene | Phase I/II | Yes | https://clinicaltrials.gov/ct2/show/NCT04565275?term=NCT04565275&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Beigene - BGB-290-AU-102 | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | Eastern | Head & Neck | Solid Tumour | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | Beigene | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT03744468?term=NCT03744468&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Binacea Pharma - BNA035-101 | BNA035 A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors BNA035-101 | St Vincent's Hospital - Medical Oncology | Head & Neck | Solid Tumour | A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors | Binacea Pharma, Inc. | Phase I | Yes | BNA035 | BNA035-101 | https://classic.clinicaltrials.gov/ct2/show/NCT05150457?term=NCT05150457&draw=2&rank=1#eligibility | Click here | Report a correction | 0 | 1 | |||||||||||
| CStone Pharmaceuticals - CS1003-101 - C-Stone | C-Stone A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid TumorsCS1003-101 | Border Medical Oncology | Head & Neck | Solid Tumour | A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors | CStone Pharmaceuticals | Phase I | Yes | C-Stone | CS1003-101 | https://classic.clinicaltrials.gov/ct2/show/NCT03475251?term=NCT03475251&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||
| Checkpoint Therapeutics - CK-301-101 | CK-301-101 A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced CancersCK-301-101 | Eastern | Head & Neck | Solid Tumour | A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers | Checkpoint Therapeutics, Inc. | Phase I | Yes | CK-301-101 | CK-301-101 | https://classic.clinicaltrials.gov/ct2/show/NCT03212404?term=NCT03212404&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||
| Corvus Pharmaceuticals - CPI-006-001 | CPI-006-001 A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced CancersCPI-006-001 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers | Corvus Pharmaceuticals, Inc | Phase I | Yes | CPI-006-001 | CPI-006-001 | https://classic.clinicaltrials.gov/ct2/show/NCT03454451?term=NCT03454451&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||
| Debiopharm International SA - DEBIO-1143 - TrilynX | TrilynX A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) DEBIO-1143 | St Vincent's Hospital - Medical Oncology | Head & Neck | Cutaneous SCC | A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) | Debiopharm International S.A | Phase III | Yes | TrilynX | DEBIO-1143 | https://classic.clinicaltrials.gov/ct2/show/NCT04459715?term=NCT04459715&draw=2&rank=1#eligibility | Click here | Report a correction | 0 | 1 | |||||||||||
| Eisai Co - E7080-G000-303 - SELECT | The Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer | Alfred Health - Endocrinology Department | Head & Neck | Thyroid | The Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer | Eisai Co., Ltd. | Phase III | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT01321554?term=NCT01321554&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Eli Lilly - J2G-MC-JZJB - LIBRETTO-531 - CT1176 | LIBRETTO-531 A mulitcentre, randomised, open-label, phase 3 trial comparing LOXO-292 to physicians choice of Cabozantinib or Vandertanib in patients with progressive, advanced, kinase inhibitor naive, RET-mutant medullary thyroid cancer J2G-MC-JZJB | Alfred Health - Endocrinology Department | Head & Neck | Thyroid | LIBRETTO-531 A mulitcentre, randomised, open-label, phase 3 trial comparing LOXO-292 to physicians choice of Cabozantinib or Vandertanib in patients with progressive, advanced, kinase inhibitor naive, RET-mutant medullary thyroid cancer J2G-MC-JZJB | Eli Lilly | Phase III | Yes | TK inhibitor. Worldwide shorage of Vandertanib. | https://classic.clinicaltrials.gov/ct2/show/NCT04211337?term=NCT04211337&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | ||||||||||||
| Epimab - EMB02X101 | A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors | Monash Health - Oncology Department | Head & Neck | Solid Tumour | A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors | Shanghai EpimAb Biotherapeutics Co., Ltd. | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04618393?term=NCT04618393&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Exelixis - XL184-311 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy | Alfred Health - Endocrinology Department | Head & Neck | Thyroid | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy | Exelixis, Inc. | Phase III | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT03690388?term=NCT03690388&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Genentech - GO43712 | A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors GO43712 | Border Medical Oncology | Head & Neck | Solid Tumour | A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors | Genentech | Phase I | Yes | GO43712 | https://classic.clinicaltrials.gov/ct2/show/NCT05487235?term=NCT05487235&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | ||||||||||||
| Haihe Biopharma - CYH33-G102 | Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | Haihe Biopharma Co., Ltd. | Phase Ib | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04586335?term=NCT04586335&draw=1&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Ignyta - RXDX-101-02 - STARTRK-2 | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | Border Medical Oncology | Head & Neck | Solid Tumour | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | Ignyta, Inc. | Phase II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02568267?term=NCT02568267&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Immutep S.A.S. - TACTI-003 - IMP321-P022 - KEYNOTE- PNC-34 | TACTI-003 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Randomized, Phase II Trial to Investigate a Soluble LAG-3 Fusion Protein, Eftilagimod Alpha (Efti; IMP321) in Combination With Pembrolizumab (PD-1 Antagonist) for First Line Treatment of Subjects With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) | Border Medical Oncology | Head & Neck | Cutaneous SCC | TACTI-003 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Randomized, Phase II Trial to Investigate a Soluble LAG-3 Fusion Protein, Eftilagimod Alpha (Efti; IMP321) in Combination With Pembrolizumab (PD-1 Antagonist) for First Line Treatment of Subjects With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) | Immutep S.A.S. | Phase II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04811027?term=NCT04811027&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Janssen-Cilag - CR108661 - RAGNAR | RAGNAR A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene AlterationsCR108661 | St Vincent's Hospital - Medical Oncology | Head & Neck | Solid Tumour | A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations | Janssen Cilag | Phase II | Yes | RAGNAR | CR108661 | https://classic.clinicaltrials.gov/ct2/show/NCT04083976?term=NCT04083976&draw=2&rank=1#eligibility | Click here | Report a correction | 0 | 1 | |||||||||||
| LaNova - LM302-01-201 | LANOVA A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-302 in Combination with Toripalimab in Patients with Advanced Solid Tumors LM302-01-201 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-302 in Combination with Toripalimab in Patients with Advanced Solid Tumors | LaNova Australia | Phase I/II | Yes | LANOVA | LM302-01-201 | https://classic.clinicaltrials.gov/ct2/show/NCT05188664?term=NCT05188664&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||
| Lawson Health - R-11-605 - SABR-COMET | SABR-COMET Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II TrialR-11-605 | Alfred Health - Radiation Oncology Department | Head & Neck | Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial | Lawson Health Research Institute | Phase II | Yes | SABR-COMET | R-11-605 | https://classic.clinicaltrials.gov/ct2/show/NCT01446744?term=NCT01446744&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | ||||||||||||
| MacroGenics - CP-MGA271-06 | A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Monash Health - Oncology Department | Head & Neck | Cutaneous SCC | A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Macrogenics Inc. | Phase II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04634825?term=NCT04634825&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Maverick Therapeutics - CP-MVC-101-01 - COBRA | COBRA A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 Conditional Bispecific Redirected Activation Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer CP-MVC-101-01 | Austin Health | Head & Neck | Solid Tumour | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 Conditional Bispecific Redirected Activation Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer | Maverick Therapeutics | Phase I/II | Yes | COBRA | CP-MVC-101-01 | https://clinicaltrials.gov/ct2/show/NCT04844073?term=NCT04844073&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||
| Maverick Therapeutics - CP-MVC-101-01 - COBRA | COBRA A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 Conditional Bispecific Redirected Activation Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer CP-MVC-101-01 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 Conditional Bispecific Redirected Activation Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer | Maverick Therapeutics | Phase I/II | Yes | COBRA | CP-MVC-101-01 | https://clinicaltrials.gov/ct2/show/NCT04844073?term=NCT04844073&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||
| Merck - MK-1084 - MK-1084-001 | 1084-001 A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRASG12C Mutant Advanced Solid Tumors MK-1084-001 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRASG12C Mutant Advanced Solid Tumors | Merck | Phase I | Yes | 1084-001 | MK-1084-001 | https://classic.clinicaltrials.gov/ct2/show/NCT05067283?term=NCT05067283&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||
| Merck - MK-145-002 | A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination With IV Pembrolizumab vs IV Pembrolizumab Monotherapy | Monash Health - Oncology Department | Head & Neck | Cutaneous SCC | A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination With IV Pembrolizumab vs IV Pembrolizumab Monotherapy | Merck | Phase II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04220866?term=NCT04220866&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Merck - MK-3475-B10 - KEYNOTEB10 | KEYNOTEB10 A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. MK-3475-B10 | St Vincent's Hospital - Medical Oncology | Head & Neck | Cutaneous SCC | A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. | Merck | Phase IV | Yes | KEYNOTEB10 | MK-3475-B10 | https://classic.clinicaltrials.gov/ct2/show/NCT04489888?term=NCT04489888&draw=2&rank=1#eligibility | Click here | Report a correction | 0 | 1 | |||||||||||
| Merck - MK-7339-007 - KEYLYNK-007 | KEYLYNK-007 A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced CancerMK-7339-007 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer | Merck | Phase II | Yes | KEYLYNK-007 | MK-7339-007 | https://classic.clinicaltrials.gov/ct2/show/NCT04123366?term=NCT04123366&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||
| Merck - MK-7902-009 - LEAP-009 | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) | Monash Health - Oncology Department | Head & Neck | Mucosal | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) | Merck | Phase II | Yes | Muhammad Alamgeer | https://classic.clinicaltrials.gov/ct2/show/NCT04428151?term=NCT04428151&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | ||||||||||||
| Molecular Templates - MT - 5111_001 | 5111_001 A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors MT-5111_001 | St Vincent's Hospital - Medical Oncology | Head & Neck | Solid Tumour | A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors | Molecular Templates Inc | Phase I/II | Yes | Tumour agnostic, HER2 altered Breast cancer expansion arm Must have HER2 expression on latest biopsy of a metastatic deposit Can be HER2 IHC2+ and non ISH-amplified Breast cancer cohort now in expansion Maximum tolerated dose reached in non-breast cohort | 5111_001 | MT-5111_001 | https://classic.clinicaltrials.gov/ct2/show/NCT04029922?term=NCT04029922&draw=2&rank=1#eligibility | Click here | Report a correction | 0 | 1 | ||||||||||
| No CTA Finance - Abbvie - M16-438 | A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands | Austin Health | Head & Neck | Solid Tumour | A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands | AbbVie | Phase I | Yes | https://clinicaltrials.gov/ct2/show/record/NCT03234712?term=NCT03234712&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - Akeso - AK117-101 | A Phase 1, Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 in Subjects With Relapsed/Refractory Advanced or Metastatic Solid Tumors or Lymphomas | Austin Health | Head & Neck | Solid Tumour | A Phase 1, Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 in Subjects With Relapsed/Refractory Advanced or Metastatic Solid Tumors or Lymphomas | Akesobio Australia Pty Ltd | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04349969?term=NCT04349969&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - Akesobio Australia Pty Ltd - AK104-101 - CT934 | A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors | Austin Health | Head & Neck | Solid Tumour | A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors | Akesobio Australia Pty Ltd | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT03261011?term=NCT03261011&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - Antengene - ATG-017-001 - ERASER | ERASER A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy in Patients With Advanced Solid Tumors and Hematological Malignancies | Austin Health | Head & Neck | Solid Tumour | A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy in Patients With Advanced Solid Tumors and Hematological Malignancies | Antengene (AUS) PTY. LTD | Phase I | Yes | ERASER | https://clinicaltrials.gov/ct2/show/NCT04305249?term=NCT04305249&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | ||||||||||||
| No CTA Finance - Antengene - ATG-101-001 - PROBE - CT1471 | PROBE A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas ATG-101-001 | Austin Health | Head & Neck | Solid Tumour | A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas | Phase I | Yes | PROBE | ATG-101-001 | https://clinicaltrials.gov/ct2/show/NCT04986865?term=NCT04986865&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | ||||||||||||
| No CTA Finance - Arcus Biosciences - AB154CSP0001 | A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | Austin Health | Head & Neck | Solid Tumour | A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | Arcus Biosciences Australia Pty Ltd. | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT03628677?term=NCT03628677&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - AstraZeneca - D7310C00001 - Interlink-1 - CT1284 | A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor | Austin Health | Head & Neck | Cutaneous SCC | A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor | AstraZeneca | Phase III | Yes | https://clinicaltrials.gov/ct2/show/NCT04590963?term=NCT04590963&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - Aulos Bioscience, Inc - CP-AU-007-01 - CT1542 | CT1542 A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer CP-AU-007-01 | Austin Health | Head & Neck | Solid Tumour | A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer | Aulos Bioscience, Inc | Phase I/II | Yes | Binds IL-2. | Andrew Weickhardt | CCTC Team 5 | CT1542 | CP-AU-007-01 | https://clinicaltrials.gov/ct2/show/NCT05267626?term=NCT05267626&draw=2&rank=1 | Click here | Report a correction | 1 | 0 | 1 | |||||||
| No CTA Finance - BMS - CA031-002 - TIM-3 | A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors | Austin Health | Head & Neck | Solid Tumour | A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors | Bristol-Myers Squibb (BMS) | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT03446040?term=NCT03446040&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - BeiGene - BGB-A317-3111 | A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors | Austin Health | Head & Neck | Solid Tumour | A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors | Beigene | Phase I/II | Yes | https://clinicaltrials.gov/ct2/show/NCT04282018?term=NCT04282018&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - BeiGene - ICP-CL-00303 | A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations | Austin Health | Head & Neck | Solid Tumour | A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations | Beigene | Phase I/II | Yes | https://clinicaltrials.gov/ct2/show/NCT04565275?term=NCT04565275&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - CStone - CS3005-101 | A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors | Austin Health | Head & Neck | Solid Tumour | A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04233060?term=NCT04233060&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | ||||||||||||||
| No CTA Finance - Eli Lilly - J2G-MC-JZJB - LIBRETTO-531 - CT1176 | LIBRETTO-531 A mulitcentre, randomised, open-label, phase 3 trial comparing LOXO-292 to physicians choice of Cabozantinib or Vandertanib in patients with progressive, advanced, kinase inhibitor naive, RET-mutant medullary thyroid cancer J2G-MC-JZJB | Alfred - Medical Oncology | Head & Neck | Thyroid | LIBRETTO-531 A mulitcentre, randomised, open-label, phase 3 trial comparing LOXO-292 to physicians choice of Cabozantinib or Vandertanib in patients with progressive, advanced, kinase inhibitor naive, RET-mutant medullary thyroid cancer J2G-MC-JZJB | Phase II | Yes | TK inhibitor. Worldwide shorage of Vandertanib. | Duncan Topliss | Report a correction | 0 | 1 | ||||||||||||||
| No CTA Finance - Exelixis - XL184-401 - EXAMINER - CT720 | A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients | Austin Health | Head & Neck | Thyroid | A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients | Exelixis, Inc. | Phase IV | Yes | https://clinicaltrials.gov/ct2/show/NCT01896479?term=NCT01896479&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - Five Prime Therapeutics - FPT155-001 - CT1051 | A Phase 1a/1b Safety and Tolerability Study of FPT155 in Patients with Advanced Solid Tumors | Austin Health | Head & Neck | Solid Tumour | A Phase 1a/1b Safety and Tolerability Study of FPT155 in Patients with Advanced Solid Tumors | Five Prime Therapeutics, Inc. | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04074759?term=NCT04074759&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - GSK - 209227 - INDUCE-4 - CT1255 | A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Austin Health | Head & Neck | Cutaneous SCC | A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | GlaxoSmithKline (GSK) | Phase III | Yes | https://clinicaltrials.gov/ct2/show/NCT04428333?term=NCT04428333&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - GSK - 209229 - INDUCE 3 - CT1170 | A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Austin Health | Head & Neck | Cutaneous SCC | A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | GlaxoSmithKline (GSK) | Phase III | Yes | https://clinicaltrials.gov/ct2/show/NCT04128696?term=NCT04128696&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - GSK - GSK204691 - INDUCE-1 | A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors | Austin Health | Head & Neck | Solid Tumour | A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors | GlaxoSmithKline (GSK) | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02723955?term=NCT02723955&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - Gilead - GS-US-548-5916 - CT1537 | ELEVATE HNSCC A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma GS-US-548-5916 | Austin Health | Head & Neck | Cutaneous SCC | A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma | Gilead | Phase II | Yes | Hui Gan | ELEVATE HNSCC | GS-US-548-5916 | https://classic.clinicaltrials.gov/ct2/show/NCT04854499?term=GS-US-548-5916&draw=2&rank=1#eligibility | Click here | Report a correction | 0 | 1 | ||||||||||
| No CTA Finance - Harbour Biomed - 4003.1 - CT1167 | A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects With Advanced Solid Tumors | Austin Health | Head & Neck | Solid Tumour | A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects With Advanced Solid Tumors | Harbour BioMed (Guangzhou) Co. Ltd | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04135261?term=NCT04135261&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - Ignyta - RXDX-101-02 - STARTRK-2 | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | Austin Health | Head & Neck | Solid Tumour | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | Ignyta, Inc. | Phase II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02568267?term=NCT02568267&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - MacroGenics - CP-MGD009-01 | Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms | Austin Health | Head & Neck | Solid Tumour | Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms | Macrogenics Inc. | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02628535?term=NCT02628535&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - Merck - MK3475-048 - KEYNOTE-048 - CT755 | A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Austin Health | Head & Neck | Cutaneous SCC | A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Merck | Phase III | Yes | Report a correction | 0 | 1 | |||||||||||||||
| No CTA Finance - Novartis - CLAG525X2101C - LAG525 | A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies | Austin Health | Head & Neck | Bladder | A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies | Novartis Pharmaceuticals Australia Pty Limited | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02460224?term=NCT02460224&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - Novartis - CLAG525X2101C - LAG525 | A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies | Austin Health | Head & Neck | Cutaneous SCC | A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies | Novartis Pharmaceuticals Australia Pty Limited | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02460224?term=NCT02460224&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - Novartis - CLAG525X2101C - LAG525 | A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies | Austin Health | Head & Neck | Prostate | A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies | Novartis Pharmaceuticals Australia Pty Limited | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02460224?term=NCT02460224&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - Novartis - CLAG525X2101C - LAG525 | A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies | Austin Health | Head & Neck | Renal Cell (Kidney) | A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies | Novartis Pharmaceuticals Australia Pty Limited | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02460224?term=NCT02460224&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - Novartis - CLAG525X2101C - LAG525 | A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies | Austin Health | Head & Neck | Solid Tumour | A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies | Novartis Pharmaceuticals Australia Pty Limited | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02460224?term=NCT02460224&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - Pfizer - B9991004 - JAVELIN Medley | A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies | Austin Health | Head & Neck | A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies | Pfizer Australia Pty Ltd | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02554812?term=NCT02554812&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | ||||||||||||||
| No CTA Finance - Pfizer - B9991016 - JAVELIN HEAD AND NECK 100 | A Randomized Double-blind Phase 3 Study Of Avelumab In Combination With Standard Of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard Of Care Chemoradiotherapy In The Front-line Treatment Of Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck | Austin Health | Head & Neck | Cutaneous SCC | A Randomized Double-blind Phase 3 Study Of Avelumab In Combination With Standard Of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard Of Care Chemoradiotherapy In The Front-line Treatment Of Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck | Pfizer | Phase III | Yes | https://clinicaltrials.gov/ct2/show/NCT02952586?term=NCT02952586&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| No CTA Finance - RAPT Therapeutics - FLX475-02 | Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer | Austin Health | Head & Neck | Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer | RAPT Therapeutics, Inc. | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT03674567?term=NCT03674567&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | ||||||||||||||
| No CTA Finance - Regeneron Pharmaceuticals - R2810-ONC-1788 - cPOST - CT1126 | cPOST A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. R2810-ONC-1788 | Border Medical Oncology | Head & Neck | Cutaneous SCC | A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. | Regeneron Pharmaceuticals | Phase III | Yes | Anti-PD-1 monoclonal antibody. | Richard Eek | cPOST | R2810-ONC-1788 | https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=NCT03969004&draw=2&rank=1#eligibility | Click here | Report a correction | 0 | 1 | |||||||||
| No CTA Finance - Regeneron Pharmaceuticals - R2810-ONC-1788 - cPOST - CT1126 | cPOST A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. R2810-ONC-1788 | Austin Health | Head & Neck | Cutaneous SCC | A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. | Regeneron Pharmaceuticals | Phase III | Yes | Anti-PD-1 monoclonal antibody. | Hui Gan | cPOST | R2810-ONC-1788 | https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=NCT03969004&draw=2&rank=1#eligibility | Click here | Report a correction | 0 | 1 | |||||||||
| No CTA Finance -Incyte - INCB99280-112 | A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors | Austin Health | Head & Neck | Solid Tumour | A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors | Incyte Corporation | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04242199?term=NCT04242199&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| PMCC Sponsored - PMC67199 - PARLuNET | Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor | PMCC - Molecular Imaging Department | Head & Neck | Neuroendocrine | Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor | PMCC Sponsored | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT05053854?term=NCT05053854&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| PMCC Sponsored - PMC67199 - PARLuNET | Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor | PMCC - Molecular Imaging Department | Head & Neck | Pancreatic | Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor | PMCC Sponsored | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT05053854?term=NCT05053854&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| PMCC Sponsored - PMC67199 - PARLuNET | Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor | PMCC - Molecular Imaging Department | Head & Neck | Sarcoma | Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor | PMCC Sponsored | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT05053854?term=NCT05053854&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| PMCC Sponsored - U1111-1156-8748 - FSRT - EYE STUDY | Can reduced dose radiotherapy delivered in standard fractionation improve the therapeutic index for stereotactic treatment of juxtapapillary choroidal melanoma? | PMCC - Moorabbin / Radiation Oncology | Head & Neck | Can reduced dose radiotherapy delivered in standard fractionation improve the therapeutic index for stereotactic treatment of juxtapapillary choroidal melanoma? | PMCC Sponsored | Phase 0/I | Yes | Report a correction | 0 | 1 | ||||||||||||||||
| PMCC sponsored - 20/044 - IMPARP-HRD - VC007 | IMPARP-HRD An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects 20/044, VC007 | Austin Health | Head & Neck | Solid Tumour | An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects | PMCC Sponsored | Phase II | Yes | IMPARP-HRD | 20/044, VC007 | https://clinicaltrials.gov/ct2/show/NCT04985721?term=NCT04985721&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||
| Regeneron Pharmaceuticals Inc - R2810-ONC-1540 - Regeneron 2 - CT823 | A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Border Medical Oncology | Head & Neck | Cutaneous SCC | A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Regeneron Pharmaceuticals | Phase II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02760498?term=NCT02760498&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Roche - CO42865 - AcceleRET-MTC | A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer. | Alfred Health - Endocrinology Department | Head & Neck | Thyroid | A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer. | F. Hoffmann-La Roche Ltd | Phase III | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04760288?term=NCT04760288&draw=1&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Senz Oncology - EOHC-1001-01 | An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer. | Monash Health - Oncology Department | Head & Neck | Other | An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer. | Senz Oncology | Phase I/II | Yes | Report a correction | 0 | 1 | |||||||||||||||
| TROG - 2009/039 - 01.09 - RTN2 | A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck | PMCC - Cancer Surgery Department | Head & Neck | Other | A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck | TROG | Phase III | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT00975520?term=NCT00975520&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| TROG - TROG 08.09 - 2009/039 - RTN2 | A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (Other IDs: TROG 08.09, 2009/039, ANZMTG 01.09) | Alfred Health - Radiation Oncology Department | Head & Neck | A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (Other IDs: TROG 08.09, 2009/039, ANZMTG 01.09) | TROG | Phase III | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT00975520?term=NCT00975520&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | ||||||||||||||
| TROG 12.01 - HPV OROPHARYNX | HPV OROPHARYNX A Randomised Trial of Weekly Cetuximab and Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma TROG 12.01 | St Vincent's Hospital - Medical Oncology | Head & Neck | Other | A Randomised Trial of Weekly Cetuximab and Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma | TROG | Phase III | Yes | HPV OROPHARYNX | TROG 12.01 | https://classic.clinicaltrials.gov/ct2/show/NCT01855451?term=NCT01855451&draw=2&rank=1#eligibility | Click here | Report a correction | 0 | 1 | |||||||||||
| Takeda - TAK-280-1501 | A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer | Monash Health - Oncology Department | Head & Neck | Solid Tumour | A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer | Takeda Oncology | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT05220098?term=NCT05220098&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| UPCOMING - Abbvie - M23-385 - CT | M23-385 A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors M23-385 | PCCTU | Head & Neck | Solid Tumour | A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors | Parexel | Phase I | PCCTU MoncC | Yes | Michael Michael | PCCTU MoncC Team | M23-385 | M23-385 | https://classic.clinicaltrials.gov/ct2/show/NCT05599984?term=M23-385&draw=2&rank=1#eligibility | Click here | Report a correction | 10 | 0 | 1 | |||||||
| UPCOMING - Actym Therapeutics - ACTM-838-01 - ACTM83801 - CT | ACTM83801 A Phase 1a/1b Open-label, Dose-escalation and Expansion Study of ACTM-838 as a Single Agent in Patients with Advanced Solid Tumors ACTM-838-01 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | A Phase 1a/1b Open-label, Dose-escalation and Expansion Study of ACTM-838 as a Single Agent in Patients with Advanced Solid Tumors | Novotech | Phase I | Yes | Andrew Haydon | ACTM83801 | ACTM-838-01 | Report a correction | 5 | 0 | 1 | |||||||||||
| UPCOMING - Anwita Biosciences - AWT020001 - CT | AWT020001 A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients with Progressive Locally Advanced or Metastatic Cancer AWT020-001 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients with Progressive Locally Advanced or Metastatic Cancer | IQVIA | Phase I/II | Yes | Mark Voskoboynik | AWT020001 | AWT020-001 | https://classic.clinicaltrials.gov/ct2/show/NCT06092580?term=AWT020-001&draw=1&rank=1#eligibility | Click here | Report a correction | 8 | 0 | 1 | |||||||||
| UPCOMING - AstraZeneca - D8470C00001 - CYAD-1 - CT | CYAD-1 A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants with Selected Advanced or Metastatic Solid Tumors. D8470C00001 | PCCTU | Head & Neck | Solid Tumour | A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants with Selected Advanced or Metastatic Solid Tumors. | AstraZeneca | Phase I/IIa | PCCTU Breast | Yes | Stephen Luen | PCCTU Breast Team | CYAD-1 | D8470C00001 | Report a correction | 10 | 0 | 1 | |||||||||
| UPCOMING - AstraZeneca - D9970C00001 - PRIMROSE - CT | PRIMROSE A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours That are MTAP Deficient D9970C00001 | PCCTU | Head & Neck | Solid Tumour | A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours That are MTAP Deficient | AstraZeneca | Phase I | PCCTU MoncB | Yes | Ben Solomon | PCCTU MoncB Team | PRIMROSE | D9970C00001 | Report a correction | 0 | 1 | ||||||||||
| UPCOMING - Australian Genomic Cancer Medicine Centre - ML43743 - MoST-TAP | MoST-TAP A single arm, open-label, phase II signal-seeking trial of tiragolumab and atezolizumab in patients with advanced solid tumours ML43743 | Bendigo | Head & Neck | Solid Tumour | A single arm, open-label, phase II signal-seeking trial of tiragolumab and atezolizumab in patients with advanced solid tumours | The George Institute | Phase II | Yes | Sam Harris | MoST-TAP | ML43743 | https://classic.clinicaltrials.gov/ct2/show/NCT06003621?term=MoST-TAP&draw=2&rank=1#eligibility | Click here | Report a correction | 0 | 1 | ||||||||||
| UPCOMING - Bendigo Sponsored - OPTION - NC | OligoProgressive Treatment for ImmunOtherapy patieNts (OPTION) OPTION | Bendigo | Head & Neck | OligoProgressive Treatment for ImmunOtherapy patieNts (OPTION) | Bendigo Health | N/A | Yes | Sam Harris | OPTION | Report a correction | 33 | 0 | 1 | |||||||||||||
| UPCOMING - Exelixis - XL092-002 - STELLAR-002 - CT | STELLAR-002 A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors XL092-002 | Cabrini | Head & Neck | Solid Tumour | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | ICON plc | Phase Ib | Yes | Gary Richardson | STELLAR-002 | XL092-002 | https://classic.clinicaltrials.gov/ct2/show/NCT05176483?term=XL092-002&draw=2&rank=1 | Click here | Report a correction | 5 | 0 | 1 | |||||||||
| UPCOMING - ImmVirX - CP-IVX001 | CP-IVX001 A phase 1 open-label, non-randomized, multi-cohort clinical study of intratumoral IVX037 as monotherapy or in combination with an immune checkpoint inhibitor in patients with advanced or metastatic solid tumors. CP-IVX001 | Western Health | Head & Neck | Solid Tumour | A phase 1 open-label, non-randomized, multi-cohort clinical study of intratumoral IVX037 as monotherapy or in combination with an immune checkpoint inhibitor in patients with advanced or metastatic solid tumors. | Novotech | Phase I | Yes | CP-IVX001 | CP-IVX001 | https://classic.clinicaltrials.gov/ct2/show/NCT05427487?term=CP-IVX001&draw=2&rank=1#eligibility | Click here | Report a correction | 0 | 1 | |||||||||||
| UPCOMING - Incyte - INCB161734-101 - CT | INCB161734-101 A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation INCB161734-101 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | IQVIA | Phase I | Yes | INCB161734-101 | INCB161734-101 | Report a correction | 0 | 1 | |||||||||||||
| UPCOMING - Incyte - INCB161734-101 - CT | INCB161734-101 A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation INCB161734-101 | PCCTU | Head & Neck | Solid Tumour | A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | IQVIA | Phase I | PCCTU EDD | Yes | Jayesh Desai | PCCTU EDD Team | INCB161734-101 | INCB161734-101 | Report a correction | 10 | 0 | 1 | |||||||||
| UPCOMING - MSD - F11-00 - MK-3475A-F11-00 | MK-3475A-F11 A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types F11-00 | Peninsula Health | Head & Neck | Solid Tumour | A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types | Merck Sharp & Dohme (MSD) | Phase II | Yes | Joanne Lundy | MK-3475A-F11 | F11-00 | Report a correction | 0 | 1 | ||||||||||||
| UPCOMING - MSD - MK4280A-010 - CT | MK4280A-010 A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors 010-00 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors | Merck Sharp & Dohme (MSD) | Phase II | Yes | Mark Voskoboynik | MK4280A-010 | 010-00 | https://classic.clinicaltrials.gov/ct2/show/NCT06036836?term=MK4280A-010&draw=2&rank=1#eligibility | Click here | Report a correction | 4 | 0 | 1 | |||||||||
| UPCOMING - Multitude - 322/23 - AMT11601 - CT | AMT-116-01 First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors AMT11601 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors | IQVIA | Phase I | Yes | Mark Voskoboynik | AMT-116-01 | AMT11601 | https://classic.clinicaltrials.gov/ct2/show/NCT05725291?term=AMT116-01&draw=2&rank=1 | Click here | Report a correction | 6 | 0 | 1 | |||||||||
| UPCOMING - PMCC - Cancer Statewide_26072023 - NC | Cancer Statewide A hybrid type III effectiveness and implementation trial of complex genomic profiling in patients with advanced cancer using three models of care in metropolitan and regional oncology centres in Victoria, Australia Cancer Statewide_26072023 | LRH | Head & Neck | Other | A hybrid type III effectiveness and implementation trial of complex genomic profiling in patients with advanced cancer using three models of care in metropolitan and regional oncology centres in Victoria, Australia | PMCC Sponsored | Phase III | Yes | Sachin Joshi | Cancer Statewide | Cancer Statewide_26072023 | Report a correction | 40 | 0 | 1 | |||||||||||
| UPCOMING - PPD - BLU-222-1101 - VELA - CT1563 | VELA A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors BLU-222-1101 | PCCTU | Head & Neck | Solid Tumour | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | PPD Australia Pty Ltd | Phase I/II | PCCTU Gynae | Yes | George Au-Yeung | VELA | BLU-222-1101 | https://clinicaltrials.gov/ct2/show/NCT05252416?term=BLU-222-1101&draw=2&rank=1 | Click here | Report a correction | 8 | 0 | 1 | ||||||||
| UPCOMING - PharmAbcine - MarkV-01 - KEYNOTE-E80 - CT | KEYNOTE-E80 A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors MarkV-01 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors | Novotech | Phase Ib | Yes | Mark Voskoboynik | KEYNOTE-E80 | MarkV-01 | https://classic.clinicaltrials.gov/ct2/show/NCT05957081?term=MarkV-01&recrs=ab&draw=2&rank=1 | Click here | Report a correction | 5 | 0 | 1 | |||||||||
| UPCOMING - PharmAbcine - MarkV-01 - KEYNOTE-E80 - CT1657 | A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors MarkV-01 | Cabrini | Head & Neck | Solid Tumour | A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors | Novotech | Phase I | Yes | Shehara Mendis | MarkV-01 | https://classic.clinicaltrials.gov/ct2/show/NCT05957081?term=MarkV-01&draw=2&rank=1#eligibility | Click here | Report a correction | 0 | 1 | |||||||||||
| UPCOMING - Servier - CL1-95012-001 - CT1463 | CT1463 A FIRST IN HUMAN PHASE 1/2 OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF PRS-344/S095012 IN PATIENTS WITH SOLID TUMORS CL1-95012-001 | PCCTU | Head & Neck | Solid Tumour | A FIRST IN HUMAN PHASE 1/2 OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF PRS-344/S095012 IN PATIENTS WITH SOLID TUMORS | Servier laboratories (AUST.) | Phase I/II | PCCTU Gynae | Yes | Linda Mileshkin | PCCTU Gynae Team | CT1463 | CL1-95012-001 | https://classic.clinicaltrials.gov/ct2/show/NCT05159388?term=CL1-95012-001&draw=2&rank=1 | Click here | Report a correction | 5 | 0 | 1 | |||||||
| UPCOMING - Tigermed - AMT-253-01 - AMT253-01 - CT | AMT253-01 First-in-Human, Phase 1 Study of AMT-253, an Anti MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors AMT-253-01 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | First-in-Human, Phase 1 Study of AMT-253, an Anti MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors | Tigermed | Phase I | Yes | Andrew Haydon | AMT253-01 | AMT-253-01 | https://classic.clinicaltrials.gov/ct2/show/NCT05906862?term=AMT-253-01&draw=2&rank=1 | Click here | Report a correction | 5 | 0 | 1 | |||||||||
| Vivace - VT3989-001 | Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene | Vivace Therapeutics, Inc | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04665206?term=NCT04665206&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Wellmarker Bio - WMS1030-101 - WM-S1-030 | A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors | Monash Health - Oncology Department | Head & Neck | Solid Tumour | A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors | Wellmarker Bio | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04801095?term=NCT04801095&draw=2&rank=1 | Click here | Report a correction | 0 | 1 | |||||||||||||
| Study Details | Site | Indication | Sub Therapeutic Area | Phase | PI |